Cabaletta Bio(CABA) - 2023 Q1 - Quarterly Report

1 • the potential advantages of our proprietary Cabaletta Approach for B cell Ablation platform, called our CABA TM platform, and our product candidates; • our ability to obtain funding for our operations, including funding necessary to initiate and complete our DesCAARTes TM trial, our MusCAARTes TMtrial, our planned clinical trial of CABA-201 and our ongoing preclinical studies of other product candidates; • the potential achievement of milestones and receipt of payments under our collaborations; • our ab ...